Bio-Techne Corporation
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kim Kelderman
- Full Time Employees
- 3,100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 614 McKinley Place N.E. Minneapolis MN United States of America 55413
- IPO Date
- Feb 9, 1989
- CIK
- 0000842023
- Website
- bio-techne.com
- Similar Companies
- Business
- Bio-Techne Corporation (NASDAQ: TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and supplies high-quality reagents, analytical instruments, and precision diagnostics for biotechnology research, clinical diagnostics, bioprocessing, and cell and gene therapy applications worldwide; the company operates through two primary segments, Protein Sciences, which provides biological reagents including cytokines, antibodies, immunoassays, cell selection kits, multicolor flow cytometry kits, multiplex assays, biologically active compounds, stem cell products, and proteomic analytical tools, and Diagnostics and Genomics, which offers diagnostic products such as advanced tissue-based in-situ hybridization assays for spatial genomic analysis and tissue biopsy, exosome-based molecular diagnostic assays, controls, calibrators, genetic and oncology kits, and clinical hematology controls; key brands encompass R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, ACD, Asuragen, Lunaphore, and BiosPacific, with over 500,000 products in its catalog, 95% manufactured in-house, supporting customers in pharmaceutical, therapeutic, diagnostics, and life science industries across more than 34 global locations including subsidiaries in Europe, China, and Hong Kong. Founded in 1976 as Research and Diagnostic Systems and renamed Bio-Techne in 2014 following its 1981 incorporation, the company employs over 3,000 people and generated approximately $1.2 billion in net sales for fiscal 2024. Recent developments include a strategic distribution partnership with Spear Bio announced in July 2025 to expand access to SPEAR UltraDetect ultrasensitive immunoassays for neurology biomarkers such as pTau 231, pTau 217, GFAP, and Nf-L, following Bio-Techne's investment in Spear Bio's 2024 Series A funding; the divestiture of its Exosome Diagnostics business to Mdxhealth SA in August 2025 for $15 million plus royalties; licensing of AI-designed NovoBody Duo molecules from Monod Bio in November 2025 to enhance its recombinant protein portfolio; launch of the ProximityScope Assay on the BOND RX platform in October 2025 for spatial protein-protein interactions research; and an AI-powered spatial biology workflow collaboration with Nucleai in November 2025 for predictive biomarker discovery in melanoma patients.
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
Madison Mid Cap Fund Q2 2026 Portfolio Activity
Conestoga SMid Cap Composite Q2 2026 Portfolio Review
Bank of Nova Scotia Sells 38,334 Shares of Bio-Techne Corp $TECH
Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?
Dimensional Fund Advisors LP Boosts Holdings in Bio-Techne Corp $TECH
INTURAI FAST TRACKS DOMECOMMAND COMMERCIALISATION WITH EUROPEAN DEFENCE TECH HUB AND SINGAPORE AIR FORCE
American Capital Management Inc. Boosts Stock Holdings in Bio-Techne Corp $TECH
Bio-Techne Corp $TECH Holdings Lowered by Bessemer Group Inc.
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?
CMB.TECH fleet update
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)